BRISTOL, Tenn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- VanderbiltReport.com, a financial news and content platform, reports that Coeptis Therapeutics (NASDAQ: COEP) is pioneering a dual-track model designed to sustain innovation while reducing reliance on dilutive funding. The biotech industry is known for high burn rates and long timelines. Companies often face an impossible choice between continuous capital raises or scaling back scientific ambitions. Coeptis is demonstrating that hybrid business models can p ...